Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis.

Autor: Karakizlis H; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany. Electronic address: Hristos.Karakizlis@innere.med.uni-giessen.de., Nahrgang C; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany., Strecker K; AID GmbH, Ebinger Straße 4, 72479 Strassberg, Germany., Chen J; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany., Aly M; Transplantation Immunology, Institute of Immunology, University Hospital Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany; Nephrology Unit, Internal Medicine Department, Assiut University, Assiut, Egypt., Slanina H; Institute of Medical Virology, Justus-Liebig-University Giessen, Schubertstraße 81, 35392 Giessen, Germany., Schüttler CG; Institute of Medical Virology, Justus-Liebig-University Giessen, Schubertstraße 81, 35392 Giessen, Germany., Esso I; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany., Wolter M; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany., Todorova D; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany., Jessen S; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany., Adamik A; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany., Ronco C; International Renal Research Institute of Vicenza, Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Via Rodolfi, 37, 36100 Vicenza, Italy; Department of Medicine (DIMED), Università di Padova, Via Giustiniani, 2, 35128 Padua, Italy., Seeger W; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany; Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Klinikstraße 33, 35392 Giessen, Germany; Max Planck Institute for Heart and Lung Research, Department of Lung Development and Remodeling, Ludwigstraße 43, 61231 Bad Nauheim, Germany., Weimer R; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany., Sester M; Department of Transplant and Infection Immunology, Saarland University, Kirrberger Straße, 66421 Homburg, Germany., Birk HW; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany., Husain-Syed F; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, 35392 Giessen, Germany; International Renal Research Institute of Vicenza, Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Via Rodolfi, 37, 36100 Vicenza, Italy. Electronic address: Faeq.Husain-Syed@innere.med.uni-giessen.de.
Jazyk: angličtina
Zdroj: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2022 Mar; Vol. 236, pp. 108961. Date of Electronic Publication: 2022 Feb 25.
DOI: 10.1016/j.clim.2022.108961
Abstrakt: Patients receiving maintenance dialysis (MD) are vulnerable to COVID-19-related morbidity and mortality. Currently, data on SARS-CoV-2-specific cellular and humoral immunity post-vaccination in this population are scarce. We conducted a prospective single-center study exploring the specific cellular (interferon-γ and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay [CMIA]) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 MD patients (six with a history of COVID-19). Our results show that MD patients exhibit a high seroconversion rate (91.7%) but the anti-spike IgG antibodies (CMIA) tend to wane rapidly after full immunization. Only 51.7% of the patients developed T cell immune response. High anti-spike IgG antibodies may predict a better cellular immunity. While patients with prior COVID-19 showed the best response after one, SARS-CoV-2-naïve patients may benefit from a third vaccine injection.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: